IMVT, NasdaqGS

Immunovant, Inc. (IMVT)

Price (as of October 1)

5.58USD

Correlations

The correlation describes the statistical relationship between the value of two assets over time. Use this relationship to bet against an asset without shorting it or diversify your portfolio more effectively. Learn how you can use correlations to your advantage.

Lowest within Industry

Symbol Correlation

CELC

Celcuity Inc.

-0.11

CYCC

Cyclacel Pharmaceuticals, Inc.

-0.09

CGEM

Cullinan Oncology, Inc.

-0.09

ANTX

AN2 Therapeutics, Inc.

-0.09

BPTH

Bio-Path Holdings, Inc.

-0.08

BIVI

BioVie Inc.

-0.08

BOLT

Bolt Biotherapeutics, Inc.

-0.08

EFTR

eFFECTOR Therapeutics, Inc.

-0.08

BTTX

Better Therapeutics, Inc.

-0.07

AURA

Aura Biosciences, Inc.

-0.06

Show more

Highest within Industry

Symbol Correlation

BWV

Blue Water Vaccines, Inc.

0.26

AMAM

Ambrx Biopharma Inc.

0.19

ABSI

Absci Corporation

0.14

ADGI

Adagio Therapeutics, Inc.

0.13

AIKI

AIkido Pharma Inc.

0.1

ALNY

Alnylam Pharmaceuticals, Inc.

0.09

ANPC

AnPac Bio-Medical Science Co., Ltd.

0.07

DICE

DICE Therapeutics, Inc.

0.07

ACET

Adicet Bio, Inc.

0.07

ABUS

Arbutus Biopharma Corporation

0.07

Show more

Profile

Sector:
Healthcare
Industry:
Biotechnology

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.